Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma

Haematologica

Volumn 91, Issue 12, 2006, Pages 1722-1723

  Wu, Ka Lung ^a   Beksac, Meral ^b   Van Droogenbroeck, Jan ^c   Amadori, Sergio ^d   Zweegman, Sonja ^e   Sonneveld, Pieter ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ANKARA UNIVERSITY   (Turkey)

^c General Hospital St Jan   (Belgium)

^d S EUGENIO HOSPITAL   (Italy)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Arsenic trioxide; Multiple myeloma; Single nucleotide polymorphisms

Indexed keywords

ARSENIC TRIOXIDE; ASCORBIC ACID; DEXAMETHASONE;

ADVANCED CANCER; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG POTENTIATION; DYSPNEA; FATIGUE; FOLLOW UP; GENETIC POLYMORPHISM; HERPES ZOSTER; HUMAN; LIVER TOXICITY; MALAISE; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; THROMBOCYTOPENIA; THROMBOEMBOLISM;

ADULT; AGED; ARSENICALS; ASCORBIC ACID; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; OXIDES; RECURRENCE;

EID: 33845952602     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-23.
2. Borad MJ, Swift R, Berenson JR. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 2005;19:154-6.
3. Abou-Jawde RM, Reed J, Kelly M, Walker E, Andresen S, Baz R, et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 2006;23:263-72.
4. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
5. Chiou HY, Hsueh YM, Hsieh LL, Hsu LI, Hsu YH, Hsieh FI, et al. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res 1997;386:197-207.